ONCOLOGY Vol 22 No 4 | Oncology

Priority Review Granted for Supplemental Use of Cervical Cancer Vaccine

April 15, 2008

Merck & Co recently announced that the US Food and Drug Administration (FDA) has accepted, and designated for priority review, the supplemental Biologics License Application (sBLA) for its recombinant human papillomavirus quadrivalent vaccine (Gardasil) for potential use in women aged 27 through 45.

Epothilones: Clinical Update and Future Directions

April 15, 2008

This article reviews recent findings from clinical trials of epothilones and discusses future directions for the use of these agents in cancer therapy, with a focus on the two most-studied epothilones to date: ixabepilone and patupilone.

Emergence of the Epothilones

April 15, 2008

Epothilones, representing a newer class of naturally occurring antimicrotubule macrolides, have emerged as cytotoxic agents with significant antitumor activity against tumors that are resistant to taxanes.

Evolving Role of the Epothilones

April 15, 2008

Ms. Donovan and Dr. Vahdat present a review of the literature on a novel class of agents, the epothilones, focusing in particular on the two most-investigated agents to date-patupilone and ixabepilone (Ixempra).

Building on the Foundation of 5-FU to Treat Metastatic Colorectal Cancer

April 15, 2008

Pohl and colleagues have provided a concise overview of current treatment options for metastatic colorectal cancer (mCRC). However, the authors do not provide personal insights as to what direction this burgeoning field will take next.

Second-Generation TKIs in Chronic Myelogenous Leukemia

April 15, 2008

Chronic myelogeneous leukemia (CML) is a biologically unique neoplasm resulting from a mutation producing a single abnormal protein that induces unregulated proliferation of myelopoiesis. Imatinib mesylate (Gleevec) profoundly inhibits the chimeric bcr/abl tyrosine kinase, and has dramatically improved the outlook for patients with CML in chronic phase.

When Imatinib Fails

April 15, 2008

The management of patients with chronic myelogenous leukemia (CML) has been altered dramatically since the introduction of tyrosine kinase inhibitors by Druker et al in the late 1990s.

Renal Cell Carcinoma: The Fastest Evolving Tumor

April 15, 2008

Renal cell carcinoma (RCC) has been considered one of the most difficult tumors to treat for about 20 years. Chemotherapy and radiotherapy have almost no efficacy in this tumor, and cytokines (interleukin [IL]-2 [Proleukin] and interferon) have remained the only available treatment for about 20 years, with a small proportion of patients benefiting from these treatments.

Targeting Metastatic Colorectal Cancer in 2008: A Long Way From 5-FU

April 15, 2008

Colorectal cancer is one of the leading causes of cancer-related death worldwide, with almost 20% of all patients presenting with metastatic disease at the time of their diagnosis. The treatment regimens and options of metastatic colorectal cancer have significantly changed in the last 10 years, leading to an improvement of response rates to about 50%, progression-free survival of about 10 months, and overall survival reaching over 2 years.